ABOUT THE EVENT
Date: Wednesday, May 13, 2026 11am–12pm EDT
Event Location: Virtual
Disease is driven by complex biological networks that remain only partially understood until experimentally resolved as a whole.
Targets and compounds advance without clear biological understanding, leading to failure.
AI and large-scale experimental data have scaled hypotheses and insights. The bottleneck now shifts to biological resolution.
Static data, including omics, cannot capture cellular biology in action, where pathways interact and drive disease.
Without experimental access to biology inside cells at AI scale and speed, target biology and compound MOA remain only partially understood.
A new paradigm brings cellular biology directly into AI: BioGPU, the biology-resolution runtime for AI. Introducing visual computing — a high-content, pathway-level imaging experimental modality in cells at scale, capturing biology in action.
This generates disease biology models of pathway and network activity in real cells.
Through the BioGPU agent, AI models chat with cells, operating on these models at runtime in a continuous loop of hypothesis, experiments, and refinement to:
- Resolve target biology — what targets do and how they are regulated, enabling causal targets to advance and weak targets to be killed
- Resolve compound MOA, how compounds modulate the system, including pathway and off-target effects
You will see this in rheumatoid arthritis and ALS case studies, where BioGPU connects to frontier AI systems, ChatGPT and Gemini AI co-scientists, operating on the BioGPU models at runtime to test and refine hypotheses, deprioritize inactive pathways, surface novel mechanisms and high-confidence targets.
Featured Speakers
A serial entrepreneur across software and biotech, he has led multiple companies from early stage to IPO and major acquisitions, including Mercury Interactive (HP, $4.5B) and Identify Software (BMC, $150M).
At Anima, he is leading a novel AI-native discovery paradigm where models become self-driving engines that visualize and compute biological pathways inside cells through iterative AI–BioGPU loops of hypothesis and experimentation.
He has led multi-target collaborations with AbbVie, Takeda, and Lilly — driving hundreds of millions in revenue and multi-billion-dollar milestones.
Yochi is widely recognized for his expertise in positioning, strategy, and company building, and for shaping breakthrough technologies into category-defining platforms.
She brings over 20 years of experience in small molecule drug discovery, preclinical development, and IND-enabling studies. Prior to co-founding Anima, Dr. Alroy held senior R&D leadership roles including VP of Discovery at Proteologics and VP R&D at Pharmos, where she led multidisciplinary teams across chemistry and biology and pharmacology groups.
Dr. Alroy is also a biotech entrepreneur, having founded and led companies such as Fusimab and ProMining Therapeutics, focused on antibody and small molecule approaches. Across her career, she has driven drug discovery programs end-to-end and collaborated extensively with academic and industry partners.
Generoso is a strategic leader in life sciences with deep expertise across multi-omics, diagnostics, biopharma, and platform-based services. Prior to joining Anima, he served as CBO at Dante Genomics. He spearheaded the launch of the Dante MyGenome Platform, enabling applications in longevity, personalized medicine, and rare disease diagnostics, and built strategic partnerships with hospitals, biopharma companies, and research institutions worldwide.
